Literature DB >> 25024072

Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer.

Brian Shuch1, Nnenaya Agochukwu1, Christopher J Ricketts1, Cathy D Vocke1, Rabindra Gautam1, Maria Merino1, W Marston Linehan1, Ramaparasad Srinivasan2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25024072      PMCID： PMC7518104          DOI： 10.1200/JCO.2013.51.0214

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  17 in total

1.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma.

Authors:  B E Baysal; R E Ferrell; J E Willett-Brozick; E C Lawrence; D Myssiorek; A Bosch; A van der Mey; P E Taschner; W S Rubinstein; E N Myers; C W Richard; C J Cornelisse; P Devilee; B Devlin
Journal:  Science       Date:  2000-02-04       Impact factor: 47.728

2.  SDHA is a tumor suppressor gene causing paraganglioma.

Authors:  Nelly Burnichon; Jean-Jacques Brière; Rossella Libé; Laure Vescovo; Julie Rivière; Frédérique Tissier; Elodie Jouanno; Xavier Jeunemaitre; Paule Bénit; Alexander Tzagoloff; Pierre Rustin; Jérôme Bertherat; Judith Favier; Anne-Paule Gimenez-Roqueplo
Journal:  Hum Mol Genet       Date:  2010-05-18       Impact factor: 6.150

3.  Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma.

Authors:  D Astuti; F Latif; A Dallol; P L Dahia; F Douglas; E George; F Sköldberg; E S Husebye; C Eng; E R Maher
Journal:  Am J Hum Genet       Date:  2001-06-12       Impact factor: 11.025

4.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase.

Authors:  Mary A Selak; Sean M Armour; Elaine D MacKenzie; Houda Boulahbel; David G Watson; Kyle D Mansfield; Yi Pan; M Celeste Simon; Craig B Thompson; Eyal Gottlieb
Journal:  Cancer Cell       Date:  2005-01       Impact factor: 31.743

Review 5.  The metabolic basis of kidney cancer.

Authors:  W Marston Linehan; Christopher J Ricketts
Journal:  Semin Cancer Biol       Date:  2012-06-13       Impact factor: 15.707

6.  Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3.

Authors:  Angelica Malinoc; Maren Sullivan; Thorsten Wiech; Kurt Werner Schmid; Cordula Jilg; Joern Straeter; Serdar Deger; Michael M Hoffmann; Alexander Bosse; Gerd Rasp; Charis Eng; Hartmut P H Neumann
Journal:  Endocr Relat Cancer       Date:  2012-05-03       Impact factor: 5.678

7.  Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma.

Authors:  Sakari Vanharanta; Mary Buchta; Sarah R McWhinney; Sanna K Virta; Mariola Peçzkowska; Carl D Morrison; Rainer Lehtonen; Andrzej Januszewicz; Heikki Järvinen; Matti Juhola; Jukka-Pekka Mecklin; Eero Pukkala; Riitta Herva; Maija Kiuru; Nina N Nupponen; Lauri A Aaltonen; Hartmut P H Neumann; Charis Eng
Journal:  Am J Hum Genet       Date:  2003-12-18       Impact factor: 11.025

8.  SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma.

Authors:  Jean-Pierre Bayley; Henricus P M Kunst; Alberto Cascon; Maria Lourdes Sampietro; José Gaal; Esther Korpershoek; Adolfo Hinojar-Gutierrez; Henri J L M Timmers; Lies H Hoefsloot; Mario A Hermsen; Carlos Suárez; A Karim Hussain; Annette H J T Vriends; Frederik J Hes; Jeroen C Jansen; Carli M Tops; Eleonora P Corssmit; Peter de Knijff; Jacques W M Lenders; Cor W R J Cremers; Peter Devilee; Winand N M Dinjens; Ronald R de Krijger; Mercedes Robledo
Journal:  Lancet Oncol       Date:  2010-01-11       Impact factor: 41.316

9.  von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.

Authors:  Toni K Choueiri; Susan A J Vaziri; Erich Jaeger; Paul Elson; Laura Wood; Ish Prasad Bhalla; Eric J Small; Vivian Weinberg; Nancy Sein; Jeff Simko; Ali-Reza Golshayan; Linda Sercia; Ming Zhou; Frederic M Waldman; Brian I Rini; Ronald M Bukowski; Ram Ganapathi
Journal:  J Urol       Date:  2008-07-17       Impact factor: 7.450

10.  Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma.

Authors:  J-J Patard; N Rioux-Leclercq; D Masson; S Zerrouki; F Jouan; N Collet; C Dubourg; B Lobel; M Denis; P Fergelot
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640
View more
  1 in total

Review 1.  Pharmacogenetic Review: Germline Genetic Variants Possessing Increased Cancer Risk With Clinically Actionable Therapeutic Relationships.

Authors:  Austin A Saugstad; Natasha Petry; Catherine Hajek
Journal:  Front Genet       Date:  2022-05-24       Impact factor: 4.772
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.